acromion GmbH
Industry / private company
Location:
Frechen,
Germany (DE)
ISNI: -
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma (2021)
Straka C, Salwender H, Knop S, Vogel M, Muller J, Metzner B, Langer C, et al.
Journal article
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials (2019)
Straka C, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, et al.
Journal article
Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma (2017)
Einsele H, Knop S, Vogel M, Mueller J, Kropff M, Metzner B, Langer C, et al.
Journal article
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial (2017)
Einsele H, Engelhardt M, Tapprich C, Mueller J, Liebisch P, Langer C, Kropff M, et al.
Journal article